Skip to main content

Table 3 Multivariable adjusted hazard ratios for breast cancer-free intervala by pre-diagnostic lipids and molecular subtypes

From: Impact of pre-diagnostic triglycerides and HDL-cholesterol on breast cancer recurrence and survival by breast cancer subtypes

 

All cases (eventsb=91)

Luminal A (eventsb=31)

Luminal B (eventsb=21)

HER2-enriched (eventsb=15)

TNBC (eventsb=24)

N

HR (95% CI)

n

HR (95% CI)

n

HR (95% CI)

n

HR (95% CI)

n

HR (95% CI)

Triglycerides

Continuous, mmol/l

446

1.01 (0.88–1.22)

224

0.88 (0.40–1.92)

94

0.76 (0.23–2.46)

41

1.01 (0.71–1.47)

87

1.12 (0.73–1.64)

Tertiles

  ≤ 0.82 mmol/l

148

1.00

76

1.00

33

1.00

13

1.00

26

1.00

 0.83–1.22 mmol/l

152

0.81 (0.47–1.40)

77

1.26 (0.51–3.11)

31

0.24 (0.06–0.89)

13

0.27 (0.04–1.91)

31

1.37 (0.37–4.98)

  ≥ 1.23 mmol/l

146

1.23 (0.71–2.13)

71

1.02 (0.38–2.68)

30

0.42 (0.12–1.52)

15

0.26 (0.03–2.54)

30

5.63 (1.64–19.3)

 p-trend

 

0.308

 

0.854

 

0.081

 

0.422

 

0.004

HDL-cholesterol/total-cholesterol ratio

Continuous

446

1.18 (0.09–15.7)

224

16.4 (0.18–1.4e4)

94

15.0 (0.04–6.2e4)

41

116 (0.00–4.3e6)

87

0.03 (0.00–6.86)

Tertiles

  ≤ 0.27

147

1.00

74

1.00

29

1.00

21

1.00

23

1.00

 0.28–0.34

149

1.16 (0.70–1.93)

66

1.52 (0.58–4.02)

36

5.13 (0.98–20.7)

13

1.27 (0.31–5.21)

34

0.58 (0.22–1.56)

  ≥ 0.35

150

1.02 (0.58–1.78)

84

1.87 (0.69–5.07)

29

2.06 (0.55–7.75)

7

2.99 (0.43–20.8)

30

0.32 (0.10–1.06)

 p-trend

 

0.808

 

0.219

 

0.344

 

0.310

 

0.060

  1. Multivariable Cox proportional hazard regression models
  2. aBreast cancer-free interval among women staged 1–3 at diagnosis
  3. bNumber of breast cancer patients with recurrence or death from breast cancer
  4. Adjusted for age (continuous), Body mass index (continuous), and current smoking (categorical) at blood sampling, age at diagnosis (continuous), and disease stage (categorical)
  5. Abbreviations: HDL high density lipoprotein, HR hazard ratio, n number of cases, TNBC triple negative breast cancer